$-1.62
(Market cap
$304,257 Mln
Revenue (TTM)
$56,306 Mln
P/E Ratio
30.7
P/B Ratio
7.9
Div. Yield
2.9 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$2,409 Mln
-
ROE
0.2 %
-
ROCE
17.7 %
-
Industry P/E
43.9
-
EV/EBITDA
15.2
-
Debt to Equity
1
-
Book Value
$--
-
EPS
$5.2
-
Face value
--
-
Shares outstanding
1,888,623,572
10 Years Aggregate
CFO
$135,202.00 Mln
EBITDA
$185,521.00 Mln
Net Profit
$116,064.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novartis AG - ADR
| 16.0 | 13.5 | 2.5 | 29.2 | 19.4 | 13.8 | 9.8 |
|
BSE Sensex
| -9.2 | 7.0 | -1.5 | -8.4 | 6.3 | 5.1 | 10.8 |
|
S&P 100
| 7.8 | -3.3 | 1.0 | 8.0 | 22.3 | 11.8 | 14.9 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Novartis AG - ADR
| 41.7 | -3.6 | 11.3 | 8.1 | -7.4 | -0.3 | 24.8 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novartis AG - ADR
|
159.9 | 304,257.3 | 56,305.9 | 10,033.1 | 25.3 | 26.5 | 30.7 | 7.9 |
| 250.1 | 37,490.2 | 10,297.2 | 348.0 | 5.5 | 1.9 | 109.8 | 2.0 | |
| 74.7 | 14,600.3 | 945.5 | -570.2 | -47.1 | -- | -- | 123.7 | |
| 62.2 | 127,714.5 | 50,034.0 | 9,243.0 | 26.0 | 42.5 | 13.8 | 5.6 | |
| 1,418.1 | 1,262,666.8 | 86,462.0 | 27,579.7 | 49.2 | 77.2 | 46.1 | 31.4 | |
| 169.4 | 211,813.9 | 30,987.0 | -3,863.0 | -4.9 | -21.1 | 17.7 | 16.2 | |
| 118.2 | 24,402.8 | 6,010.8 | 403.4 | 13.3 | 7.2 | 61.4 | 4.3 | |
| 267.4 | 662,491.8 | 99,335.0 | 16,095.0 | 18.8 | 19.8 | 41.8 | 8.0 | |
| 144.5 | 361,021.2 | 67,302.0 | 2,453.0 | 0.2 | 10.7 | 116.1 | 8.3 | |
| 20.8 | 63,923.4 | 4,734,857.2 | 386,370.2 | 14.8 | 5.1 | -- | 1.3 |
Shareholding Pattern
View DetailsAbout Novartis AG - ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart... failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Read more
-
Chief Executive Officer
Dr. Vasant Narasimhan M.D.
-
Chief Executive Officer
Dr. Vasant Narasimhan M.D.
-
Headquarters
Basel
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Novartis AG - ADR
What is the current share price of Novartis AG - ADR Today?
The share price of Novartis AG - ADR is $159.90 (NYSE) as of 03-Nov-2026 13:44 EST. Novartis AG - ADR has given a return of 19.36% in the last 3 years.
What is the current PB & PE ratio of Novartis AG - ADR?
The P/E ratio of Novartis AG - ADR is 30.74 times as on 30-Oct-2026, a 30 discount to its peers’ median range of 43.90 times.
The P/B ratio of Novartis AG - ADR is 7.92 times as on 30-Oct-2026, a 1 discount to its peers’ median range of 8.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
18.92 |
5.77 |
2024 |
16.33 |
4.43 |
2023 |
14.04 |
4.47 |
2022 |
28.04 |
3.29 |
2021 |
8.20 |
2.91 |
What is the 52 Week High and Low of Novartis AG - ADR?
The 52-week high and low of Novartis AG - ADR are Rs 170.46 and Rs 122.86 as of 04-Nov-2026.
What is the market cap of Novartis AG - ADR?
Novartis AG - ADR has a market capitalisation of $ 304,257 Mln as on 30-Oct-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Novartis AG - ADR?
Before investing in Novartis AG - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.